INDIANAPOLIS (AP) — Eli Lilly & Co. said Monday the Food and Drug Administration approved the bipolar depression drug Symbyax as a therapy for treatment-resistant depression. The new indication applies to adult patients who have not responded to two separate rounds of therapy with different antidepressants. The FDA also approved the combined use of Zyprexa and fluoxetine, or Prozac, as a treatment for depression and treatment-resistant depression. Zyprexa is already approved for schizophrenia and bipolar disorder.
Related Articles Read More >
Confidently navigate the transition from bench to batch
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
